Opinion
Video
NCCN Guidelines and Treatment Insights for Desmoid Tumors
Delve into the NCCN guidelines and contemporary treatments for desmoid tumors and explore the multidisciplinary approach, limitations, and current standard care options for enhanced patient outcomes.
This is a video synopsis/summary of a Peer Exchange involving Ryan Haumschild, PharmD, MS, MBA; Tony Phillip, MD; Mrinal Gounder, MD; Ravin Ratan, MD, MEd; and Derek Van Amerongen, MD, MS.
Haumschild delves into the current standards of care and treatment landscape for desmoid tumors, referencing the National Comprehensive Cancer Network (NCCN) guidelines. Ratan emphasizes the guidelines’ strategic division of tumors into those at risk of complications and those not, promoting active surveillance for the majority. The guidelines avoid overprescription, reflecting the need for tailored, multidisciplinary approaches. Van Amerongen highlights the significance of NCCN guidelines as a gold standard, guiding health plan policies to align with the latest treatment algorithms.
Gounder details the current standard of care, emphasizing a shift from surgery to up-front watchful waiting. Individualized decision-making considers patient symptoms, tumor progression, and location. Local approaches, including high-intensity focused ultrasound and transarterial chemoembolization, complement systemic therapies such as traditional cytotoxic chemotherapies, tyrosine kinase inhibitors, and γ-secretase inhibitors. Clinical trials remain crucial for exploring novel options, ensuring optimal care for rare diseases such as desmoid tumors. The discussion underscores the importance of aligning treatment decisions with NCCN guidelines, providing valuable insights for both providers and payers in managing desmoid tumors effectively.
Video synopsis is AI generated and reviewed by AJMC® editorial staff.
